Early treatment with Drotrecogin alfa (activated) was associated with reduced hospital resource use in adult severe sepsis patients with two or more organ dysfunctions at baseline: results from ENHANCE

Documenti analoghi

• Drotrecogin alfa (activated) in the subgroup of patients with multiple organ dysfunction (MOD) during a global, single-arm, open-label trial in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS
  di: Vincent, J, et al.
  Pubblicazione: (2004)
• Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated)
  di: Dhainaut, J, et al.
  Pubblicazione: (2008)
• Severe sepsis and drotrecogin alfa (activated) use: results from the PROGRESS registry
  di: Beale, R, et al.
  Pubblicazione: (2007)
• Introduction: severe sepsis and drotrecogin alfa (activated)
  di: Artigas, Antonio, et al.
  Pubblicazione: (2007)
• The efficacy of Drotrecogin alfa (activated) during a global, single-arm, open-label trial in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS
  di: Vincent, J, et al.
  Pubblicazione: (2004)